• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OncoSec $30m fundraise threatened by spat

December 2, 2019 By Chris Newmarker

OncoSecOncoSec Medical (NSDQ:ONCS) is embroiled in a lawsuit and proxy war over a $30 million money-raise as it seeks to continue development of its cancer treatment technology.

The company — headquartered in San Diego and Pennington, N.J. — sent a letter to shareholders today in which it countered what it described as false and misleading statements by South Korea–based investor Alpha Holdings, which is seeking to stop a $30 million cash infusion from China Grand Pharmaceutical and Healthcare Holdings and its U.S. affiliate Sirtex Medical Holdings.

Alpha Holdings also has a lawsuit underway in the Eighth Judicial District Court in Las Vegas to halt a scheduled Jan. 17, 2020 shareholder vote on the deal.

OncoSec’s lead technology Tavo uses electroporation, in which an electrical field increases cell membrane permeability. Tavo is meant to deliver DNA-based interleukin-12 (IL-12) directly into tumors in order to produce an immune response.

The company’s stock lost more than half its value in November 2018 after the release of preliminary results of a study evaluating the use of Tavo with Merck‘s (NYSE:MRK) intravenous immunotherapy drug, Keytruda, on people with advanced skin cancer. Despite the negative response on Wall Street, researchers described the 10% response rate in the preliminary results as meaningful.

OncoSec’s stock is presently trading around $2 per share.

Alpha Holdings officials say they want a thorough sale process to maximize value for all stockholders and ensure that the company can realize future upside. But OncoSec CEO Daniel O’Connor said today in the shareholders letter that the company only had $25 million in cash at the end of July and is burning through $2.5 million a month.

“Due to limitations under the federal securities laws and current market conditions, even if we sold nearly every share available to us today (approximately 12 million) we would only be able to raise approximately $8 million at most, not considering discount pricing and significant warrant coverage, both of which would likely be included in such a deal — compared to the $30 million we would receive from the transaction by selling the same number of shares,” O’Connor said.

Over the last 18 months, OncoSec, according to O’Connor, spent 18 months working with Destum Partners, PierCap Partners, Sage Group and Torreya Partners to explore potential licensing opportunities, financings and strategic transactions. None of the resulting discussions panned out.

OncoSec plans to vigorously defend itself against Alpha Holdings’ litigation in Nevada. “Unfortunately, this is forcing the company to spend millions of dollars on these multiple actions, diverting those funds away from our clinical trials and other critical aspects of our business,” O’Connor said.

 

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Oncology Tagged With: Alpha Holdings, Cancer, China Grand Pharmaceutical and Healthcare Holdings, OncoSec Medical, Sirtex Medical Holdings

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS